Literature DB >> 11801449

Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.

Marina Ferrarini1, Elisabetta Ferrero, Lorenzo Dagna, Alessandro Poggi, Maria Raffaella Zocchi.   

Abstract

Down-regulation of expression of MHC alleles, as well as tumor-specific antigens, is observed frequently during tumor progression, resulting in an impairment of MHC-restricted, alphabeta-T-cell-mediated, tumor-specific immunity. Given the unique set of antigens recognized and the lack of requirement for classical antigen-presenting molecules, gammadelta T cells might, therefore, represent a nonredundant system in anticancer surveillance, as proposed for the immune response against pathogens. Evidence that gammadelta and alphabeta T cells make distinct contributions to anticancer surveillance has been provided recently in mice. Here, we discuss the potential role played by resident Vdelta1(+) and circulating Vdelta2(+) T cells in the defense against solid tumors and hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801449     DOI: 10.1016/s1471-4906(01)02110-x

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  35 in total

1.  ATP release and autocrine signaling through P2X4 receptors regulate γδ T cell activation.

Authors:  Monali Manohar; Mark I Hirsh; Yu Chen; Tobias Woehrle; Anjali A Karande; Wolfgang G Junger
Journal:  J Leukoc Biol       Date:  2012-06-29       Impact factor: 4.962

2.  Complementary function of gamma delta T-lymphocytes and dendritic cells in the response to isopentenyl-pyrophosphate and lipopolysaccharide antigens.

Authors:  Angelo Martino; Rita Casetti; Alessandra D'Alessandri; Alessandra Sacchi; Fabrizio Poccia
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

3.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

Review 4.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 5.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 6.  Gammadelta T-cells: potential regulators of the post-burn inflammatory response.

Authors:  Martin G Schwacha
Journal:  Burns       Date:  2008-10-31       Impact factor: 2.744

7.  Zoledronic acid sensitizes rhabdomyosarcoma cells to cytolysis mediated by human γδ T cells.

Authors:  Ling-Ling Sun; Zheng-Liang Zhang; Ying-Jun Li; Sheng-Dong Wang; Heng-Yuan Li; Bing-Hao Li; Ting Zhu; Zhao-Ming Ye
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

8.  Gamma/delta T cells in patients with acute brucellosis.

Authors:  S S Kilic; H H Akbulut; M Ozden; V Bulut
Journal:  Clin Exp Med       Date:  2008-12-02       Impact factor: 3.984

9.  Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation.

Authors:  Lionel Couzi; Yann Levaillant; Abdellah Jamai; Vincent Pitard; Regis Lassalle; Karin Martin; Isabelle Garrigue; Omar Hawchar; François Siberchicot; Nicholas Moore; Jean-François Moreau; Julie Dechanet-Merville; Pierre Merville
Journal:  J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 10.121

10.  Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS.

Authors:  Jean-Saville Cummings; Cristiana Cairo; Cheryl Armstrong; Charles E Davis; C David Pauza
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.